Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| BlossomHill Therapeutics | 2025 | Series B | $84.0M | San Diego |
| Kymera Therapeutics | 2025 | Post Ipo Equity | $602.0M | Cambridge |
| Structure Therapeutics | 2025 | Post Ipo Equity | $747.5M | South San Francisco |
| Nuvalent | 2025 | Post Ipo Secondary | $500.0M | Cambridge |
| Artios Pharma | 2025 | Series D | $115.0M | Cambridge |
| Bambusa Therapeutics | 2025 | Series A | Undisclosed | Boston |
| Annexon Biosciences | 2025 | Post Ipo Equity | $86.3M | South San Francisco |
| Centessa Pharmaceuticals | 2025 | Post Ipo Equity | $250.0M | Cambridge |
| 4D Molecular Therapeutics | 2025 | Post Ipo Equity | $100.0M | Emeryville |
| Sonoma Biotherapeutics | 2025 | Grant | $300K | South San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | BlossomHill Therapeutics | Series B | $84.0M | San Diego, United States |
| 102 | Kymera Therapeutics | Post Ipo Equity | $602.0M | Cambridge, United States |
| 103 | Structure Therapeutics | Post Ipo Equity | $747.5M | South San Francisco, United States |
| 104 | Nuvalent | Post Ipo Secondary | $500.0M | Cambridge, United States |
| 105 | Artios Pharma | Series D | $115.0M | Cambridge, United Kingdom |
| 106 | Bambusa Therapeutics | Series A | Undisclosed | Boston, United States |
| 107 | Annexon Biosciences | Post Ipo Equity | $86.3M | South San Francisco, United States |
| 108 | Centessa Pharmaceuticals | Post Ipo Equity | $250.0M | Cambridge, United States |
| 109 | 4D Molecular Therapeutics | Post Ipo Equity | $100.0M | Emeryville, United States |
| 110 | Sonoma Biotherapeutics | Grant | $300K | South San Francisco, United States |
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Bambusa Therapeutics operates as biotechnology company.
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Owlet Baby Care offers a health monitor that allows parents to view their child's vital signs in real-time.
AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Xos Trucks specializes in the field of manufacturing fully electric commercial vehicles.
PepGen is empowering nucleic acid therapeutics to go the distance.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.
Janus Henderson Investors has invested in 175 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Therapeutics, Health Care, Life Science, Pharmaceutical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $12.5B.
Janus Henderson Investors's average investment size is $129.0M across its portfolio of 175 companies.
Recent Janus Henderson Investors portfolio additions include BlossomHill Therapeutics, Kymera Therapeutics, Structure Therapeutics, Nuvalent, Artios Pharma. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors